Before acquisition, Applied Therapeutics reduced workforce by approximately 46% and implemented cost-containment measures, reflecting challenges in its development pipeline. The company completed FDA Type C meetings for govorestat in CMT-SORD and received FDA written feedback on galactosemia data, evaluating next steps.
Cyborg Score Rationale
The company was acquired following strategic pressures, indicating failed attempts to execute as an independent entity. Cash position declined from $79.4M (Dec 2024) to $50.8M with mounting G&A expenses of $17.7M and net loss of $21.8M, demonstrating unsustainable unit economics.
Top Insights
Cycle Pharmaceuticals completed acquisition on February 3, 2026, integrating govorestat into Cycle's portfolio
Shareholders received $0.088 per share in cash plus contingent value rights potentially paying up to $0.40 per CVR upon FDA approvals and sales milestones
Company executed 46% workforce reduction and cash preservation measures prior to acquisition
INSPIRE Phase 3 trial data presented 12-month and new 18/24-month results at PNS 2025 Annual Meeting for CMT-SORD
Named Competitors
Rare metabolic disease treatments — Parent company integrating govorestat into broader rare disease portfolio
Recent Developments
(February 2026) Acquisition completed by Cycle Group Holdings Limited
(January 2026) Stockholders recommended tender of shares following offer extension
(December 2025) Cycle Pharmaceuticals announced acquisition agreement
(November 2025) Corporate updates announced workforce reduction and strategic review
Open the full interactive Applied Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.